Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200

Blood Advances · Published 2026-07-31 · DOI 10.1182/bloodadvances.2026020293

Free full text

Authors (25)

Qaiser Bashir, Peter F Thall, Jitesh Kawedia, Xun Xu, Cristina G Knape, Ruby Delgado, Yago Nieto, Neeraj Y Saini, Yosra Aljawai, Samer A Srour, Jeremy L. Ramdial, Chitra Hosing, Uday R. Popat, Betul Oran, Partow Kebriaei, Sairah Ahmed, Oren Pasvolsky, Krina K. Patel, Sheeba K. Thomas, Mahmoud R. Gaballa, Jing Christine Ye, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H Qazilbash

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Bashir, Q., Thall, P., Kawedia, J., et al. (2026). Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200. Blood Advances. https://doi.org/10.1182/bloodadvances.2026020293

Related articles

• Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry · Blood Advances · 2026 · Same journal
• Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development · Blood Advances · 2026 · Same journal
• Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia · Blood Advances · 2026 · Same journal
• Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q · Blood Advances · 2026 · Same journal
• Reframing Hematologic and Thrombovascular Care for Transgender and Gender-Diverse Individuals: A Scoping Review · Blood Advances · 2026 · Same journal
• Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant · Blood Advances · 2026 · Same journal
• Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion dependent thalassemia in LMICs · Blood Advances · 2026 · Same journal
• The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach · Blood Advances · 2026 · Same journal
• A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia · Blood Advances · 2026 · Same journal
• In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway · Blood Advances · 2026 · Same journal